Loading provider…
Loading provider…
Hematology & Oncology Physician in Houston, TX
NPI: 1366541054Primary Employer
Physicians Referral Service
mdanderson.org
HQ Phone
Get M.D. Richard's Phone Numberphone_androidMobile
Get M.D. Richard's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTX State Medical License
CA State Medical License
1976
FL State Medical License
2021
AZ State Medical License
2023 - 2027
GA State Medical License
2023 - 2027
TN State Medical License
2023 - 2027
LA State Medical License
2023 - 2026
WA State Medical License
2023 - 2026
AL State Medical License
2023 - 2025
MS State Medical License
2023 - 2025
OK State Medical License
2020 - 2025
TX State Medical License
1990 - 2025

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Hematology and Medical Oncology
1978 - 1980
Los Angeles County-Harbor-UCLA Medical Center
Residency • Internal Medicine
1975 - 1978
Pritzker School of Medicine
pritzker.uchicago.edu
Medical School
Until 1975
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 64 | 280 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 35 | 49 |
| 3 | 38206Collection of stem cells for transplantation | 17 | 17 |
| 4 | 36514Mechanical separation of plasma from opening blood | 12 | 12 |
Authors: Michael Andreeff, Hagop Kantarjian
Journal: Leukemia
Prognostic value of EMT-circulating tumor cells in metastatic breast can-cer patients undergoing high-dose chemotherapy with autologous hematopoietic stem cell transplantation
Authors: Massimo Cristofanilli, Yago Nieto
Publication Date: 2012-12
Authors: Elizabeth Shpall, Betul Oran, Gheath Al-Atrash, Hagop Kantarjian, Amin Alousi, Rohtesh Mehta, Uday Popat, Koichi Takahashi
Journal: Leukemia
Publication Date: 2021-06-16
Lead Sponsor: M.D. Anderson Cancer Center
Intervention / Treatment: DRUG: Cyclophosphamide, DRUG: Fludarabine, PROCEDURE: Peripheral Blood Stem Cell Transplantation, RADIATION: Total-Body Irradiation, BIOLOGICAL: Anti-Thymocyte Globulin, BIOLOGICAL: Cytokine-treated Veto Cells
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: OTHER: Standard of Care, DRUG: Midostaurin
Lead Sponsor: M.D. Anderson Cancer Center
Collaborators: Bellicum Pharmaceuticals
Intervention / Treatment: DRUG: Melphalan, BEHAVIORAL: Questionnaire, DRUG: Tacrolimus, DRUG: Fludarabine, DRUG: Methylprednisolone, DRUG: G-CSF, DRUG: Alemtuzumab, PROCEDURE: Donor Lymphocyte Infusion (DLI), DRUG: AP1903, PROCEDURE: Stem Cell infusion, DRUG: Mini Methotrexate